STARflo TM Glaucoma Implant Clinical Experience Program in Real-World

  • Research type

    Research Study

  • Full title

    STARflo Glaucoma lmplant Clinical Experience Program in a Real-World Patient Population

  • IRAS ID

    210300

  • Contact name

    Marie-Claude MAUBREY

  • Contact email

    marie-claude@istarmed.com

  • Sponsor organisation

    iSTAR Medical

  • Clinicaltrials.gov Identifier

    NCT02825264

  • Duration of Study in the UK

    7 years, 0 months, 1 days

  • Research summary

    The aim of this Clinical Experience Program is to document patient’s benefit following implantation of the STARflo Implant in patients treated in a day to day clinical setting and to learn about surgical practices.
    This Clinical Experience Program is being initiated to expand the surgical and clinical practice knowledge about the use of STARflo for reducing intraocular pressure (lOP) in a “real world" population of patient.
    Patients suffering from open angle glaucoma or in some cases of narrow angle glaucoma (as per instruction for use (IFU)) and implanted with STARflo within five past years, will be eligible for this research.
    This Clinical Experience Program is open to any investigative site willing to contribute and approved to do so as per local regulation. Investigator selected to participate to this program must have implanted at least one STARflo in indicated population.
    Patient data will be collected retrospectively or prospectively after patient’s signed approval to do so.
    This research is designed as a registry program. Therefore participating patients will not undergo any intervention in addition of standard practice exams. This research plans to collect effectiveness of STARflo implant, surgery complications and medical device related adverse events over a period of 60 months after participating patient’s implantation surgery.

  • REC name

    London - Brighton & Sussex Research Ethics Committee

  • REC reference

    16/LO/1461

  • Date of REC Opinion

    12 Oct 2016

  • REC opinion

    Further Information Favourable Opinion